Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18515377 | 0.86 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL16209818 | 0.83 | KMT2A (0.47) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL14559049 | 0.81 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL20425219 | 0.81 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL23085379 | 0.81 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30510292 | 0.81 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL25182936 | 0.81 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL20371103 | 0.81 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL31170925 | 0.80 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL831614 | 0.80 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3276003-B1 | SINGLE-CHAIN NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION CONTROL ABILITY | BONAC CORP (JP) | 2022-07-20 | — | — | EP | disclosed |
| US-11142769-B2 | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability | BONAC CORPORATION (JP) | 2021-10-12 | — | — | US | disclosed |
| US-10238752-B2 | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function | BONAC CORPORATION (JP) | 2019-03-26 | — | — | US | disclosed |
| US-20180119151-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION REGULATING ABILITY | BONAC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3276003-A1 | SINGLE-CHAIN NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION CONTROL ABILITY | Bonac Corporation (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170306325-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR REGULATING EXPRESSION OF GENE HAVING DELIVERING FUNCTION | BONAC CORPORATION (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9663784-B2 | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function | BONAC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20150105443-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR REGULATING EXPRESSION OF GENE HAVING DELIVERING FUNCTION | BONAC CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2857513-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR REGULATING EXPRESSION OF GENE HAVING DELIVERING FUNCTION | Bonac Corporation (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119151-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION REGULATING ABILITY | ZFX, ZFR, SRRT | KMT2A 1325/4885FABP5 1834/4885FABP7 1081/4885 |
| US-11142769-B2 | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability | ZFX, ZFR, SRRT | KMT2A 1325/4885FABP5 1834/4885FABP7 1081/4885 |
| US-10238752-B2 | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function | ZFX, RPRD2, YBX1 | KMT2A 1473/4885FABP5 1828/4885FABP7 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.